Therapy of Primary Liver Cancer

Mei Feng; Yisheng Pan; Ruirui Kong; Shaokun Shu

doi:10.1016/j.xinn.2020.100032

Therapy of Primary Liver Cancer

Innovation (Camb). 2020 Aug 28;1(2):100032. doi: 10.1016/j.xinn.2020.100032. Epub 2020 Aug 10.

Authors

Mei Feng^{1

2}, Yisheng Pan², Ruirui Kong¹, Shaokun Shu^{1

3

4}

Affiliations

¹ Translational Cancer Research Center, Peking University First Hospital, Beijing 100034, China.
² Department of General Surgery, Peking University First Hospital, Beijing 100034, China.
³ Department of Biomedical Engineering, Peking University, Beijing 100871, China.
⁴ Peking University Cancer Hospital, Beijing 100142, China.

Abstract

Primary liver cancer (PLC) is a fatal disease that affects millions of lives worldwide. PLC is the leading cause of cancer-related deaths and the incidence rate is predicted to rise in the coming decades. PLC can be categorized into three major histological subtypes: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined HCC-ICC. These subtypes are distinct with respect to epidemiology, clinicopathological features, genetic alterations, and clinical managements, which are thoroughly summarized in this review. The state of treatment strategies for each subtype, including the currently approved drugs and the potential novel therapies, are also discussed.

Keywords: PLC therapy; combined HCC-ICC; hepatocellular carcinoma; intrahepatic cholangiocarcinoma; primary liver cancer.

Publication types

Review